MIRM Q4 2022 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$28M+789.3% YoY

Gross Profit

$23M83.9% margin

Operating Income

-$34M-122.4% margin

Net Income

-$36M-130.5% margin

EPS (Diluted)

$-0.97

QoQ Revenue Growth

+48.6%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$35M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$353M

Total Liabilities

$211M

Stockholders' Equity

$142M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28M	$3M	+789.3%
Gross Profit	$23M	$1M	+1795.7%
Operating Income	-$34M	-$46M	+25.0%
Net Income	-$36M	$58M	-163.3%

Revenue Segments

Product

$28M100%